INTRODUCTION

The leishmaniases, a group of diseases caused by infection with various species of the protozoan parasite genus *Leishmania*, are endemic in 88 countries. Together, ~350 million people are at risk of infection with these parasites with the leishmaniases having an overall prevalence of 12 million cases worldwide and accounting for about 60,000 deaths annually (Desjeux, 2001). Expansion of disease and the sharp rise in prevalence has been linked to migration of non-immune people into endemic areas as well as environmental changes resulting in the expansion of the insect vector habitats (WHO, 2010). The latter, in particular, has the potential to widen the geographic reach of the vector and introduce leishmania transmission into previously unaffected areas. Although an estimated 2 million new cases occur annually (~1.5 million cases of cutaneous leishmaniasis (CL) and 500,000 of visceral leishmaniasis (VL)) – leishmaniases still represent a neglected tropical disease and have not been considered as attractive vaccine targets by industry. Despite efforts that now span more than a century, a licensed vaccine for use in humans is not yet available.

FIRST-GENERATION VACCINES FOR LEISHMANIASES

The earliest records of vaccination against leishmaniasis date back several hundred years, when leishmanization was practiced in the Middle East. Bedouin tribal societies traditionally exposed their children to sandfly bites in order to protect them from facial lesions. In some cases pus from active lesions was also inoculated by excoriation of the recipient’s arm or thigh (Greenblatt, 1980). This technique was refined in the early 1900s when culture conditions were established for leishmania promastigotes, which were then used to both prevent and treat active disease (Ross, 1912; Wenyon, 1928; Greenblatt, 1980). These studies formed the basis for large-scale vaccination trials that were carried out in the Soviet Union, Israel, and Iran (Greenblatt, 1980; Nadim et al., 1983). The success in these trials depended critically on the viability and infectivity of the injected organisms. Organisms which had lost virulence were shown to induce delayed-type hypersensitivity but did not protect from subsequent natural infection. Additionally, use of live vaccines had many problems, including the development of large uncontrolled skin lesions, exacerbation of postular lesions, and other skin diseases, which paved the way for trials using killed parasites but conflicting results made this approach unpopular (Handman, 2001). However, this strategy regained popularity in the late 1970s after the route of immunization was found to be crucial for its efficacy (Mayrink et al., 1979; Greenblatt, 1980; Handman, 2001). Convit and colleagues used a combination of killed *L. mexicana* or *L. braziliensis* promastigotes and *Mycobacterium bovis* Bacille Calmette-Guérin (BCG) therapeutically against leishmaniasis in South America. Vaccination of clinically defined patients appeared to induce a high cure rate...
even in severe cases and was accompanied by the development of TH1 helper type 1 (Th1) immune responses in the recipients (Castes et al., 1989; Cabrera et al., 2000). Prophylactic vaccinations with killed parasites formulated with or without BCG, however, have been less successful (Armitage et al., 1998; Sharifi et al., 1998; Momeni et al., 1999). Although two of the most successful vaccines used to date (against small pox and polio, respectively) are live pathogens, that strategy does not appear feasible for leishmaniasis. Results from several clinical trials using whole Leishmania (involving either live or killed parasites) vary from 0 to 75% efficacy against CL (Coler and Reed, 2005; The Working Group on Research Priorities for Development of Leishmaniasis Vaccines, 2011). Several investigators are investigating the potential of live-attenuated vaccines for CL. Some genetically or chemically attenuated parasites appear to persist indefinitely without pathology and confer long lasting protection in mice (Titus et al., 1995; Papadopoulos et al., 2002; Uzonna et al., 2005; Davoudi et al., 2005; Daneshvar et al., 2010; Birnbaum et al., 2012). Although not yet evaluated in clinical trials, it is conceivable that these could offer lasting protection in humans. Given their complex and heterogeneous nature, however, it is unclear how they will overcome current vaccine regulations and release criteria. Studies using these crude vaccine approaches, though not ideal, have however proved that it is possible to induce protection and suggest that this is also achievable with parasite components. Several investigators have addressed this issue using the experimental murine model of CL. The simplicity and pliable nature of this model (differential outcomes dependent upon mouse strain and infective dose) has permitted researchers to address basic questions of immunity and have provided significant insight regarding the development of cellular immune responses.

**INSIGHT INTO CELLULAR IMMUNITY: THE CL MOUSE MODEL**

Experimental murine infection with *L. major* has facilitated our understanding of the Th1/Th2 paradigm, the development of helper T cells during an infection and factors that regulate their maintenance (Lockley and Scott, 1991; Scott, 1991; Reed and Scott, 1993). Additionally, this model has revealed genetic mechanisms of protection conferred by Th1 cells in resistant strains and susceptibility induced by Th2 cells in the BALB/c model (Reed and Scott, 1993; Scharf, Kersten et al., 1995; Park et al., 2000; Hutchins et al., 2005). Most inbred mouse strains (e.g., C57Bl/6, CBA/J, and C3H) are considered resistant to infection with *L. major*, these strains develop a mammal lesion that subsides within 6–8 weeks (Scott, 1998). Healing in resistant mice infected with *L. major* is associated with the development of Th1 cells that produce IFN-γ, which is necessary for activation of macrophages and the production of nitric oxide (NO), the key effector molecule for intracellular amastigotes (Liew et al., 1990a,b; Stenger et al., 1994). These mice are also protected against additional *L. major* challenges. In contrast, BALB/c mice are highly susceptible to *L. major* infection; parasite burdens can become extremely high, with lesions progressing until ulceration. Deconstructing the cause of BALB/c mice to protect against infection helped to identify the crucial roles of IL-4 and IL-13 in the promotion and expansion of Th2 cells. Both the initial development and maintenance of Th1 cells in infected mice is dependent on the presence of IL-12 produced by dendritic cells. Treatment of BALB/c mice with recombinant IL-12 helps to prevent against infection while, conversely, treatment of resistant strains with anti-IL-12 promotes the development of a Th2 response and susceptibility (Henziel et al., 1993, 1998; Hondowicz et al., 1997, 2005; Fernandez-Botran et al., 1999; Park et al., 2000; Kedzierski et al., 2008). Another key cytokine that has been shown to regulate disease outcome is IL-10. Disruption of the IL-10 gene confers resistance while over-expression of this gene in resistant strains renders them susceptible. IL-10 appears to mediate its effect by blocking the activating effects of IFN-γ. In addition to deactivating macrophages and inhibiting intracellular parasite killing, IL-10 can also directly inhibit Th1 cell development and their production of IFN-γ (Kane and Moser, 2001). Furthermore, IL-10 production by natural CD4^+ CD25^+ regulatory T cells plays an important role in disease pathology (Belkaid et al., 2002; Mendez et al., 2004).

Importantly, given its flexibility and broad understanding, the CL mouse model has helped construct a syllogism that supports a platform for adjuvant discovery/selection. By virtue of its simplicity, it has also facilitated the study the mechanism of action of these adjuvants in vivo (Mendez et al., 2003; Darrah et al., 2007, 2010). Among the adjuvants investigated using this model are the TLR4 agonist-monophosphoryl lipid A (MPL®), the TLR7/8 agonist – imiquimod, the TLR9 agonist – CpG, and the immunostimulatory complexes (ISCOM; Figure 1). There is some irony that very few of these adjuvants have actually been evaluated against human CL, although this lack of progression is at least partially attributable to the fact that human CL is a much more complex disease than the experimental model. These adjuvants have, however, helped scientists understand the need for certain types of immune responses at specific stages of disease, which in turn, could aid in designing an effective vaccine for human CL. This review focuses on adjuvants that have been tested in experimental CL, their effects when applied in human CL, and how they have helped advance our understanding of the disease.

**ADJUVANT BIOLOGY AND THE ADVANCEMENT TOWARD SECOND GENERATION VACCINES**

Innate immunity forms the host’s first line of defense against microbial invasion. Targeting innate immune receptors with adjuvants is a logical strategy, particularly for infections of innate cells such as Leishmaniasis. Studies of adjuvants began more than a hundred years ago with the discovery that an acute bacterial infection could induce regression in a concurrent malignant tumor (Tokunaga, 1990; Ricks, 1996). Surprisingly however, the “immunologist’s dirty little secret” (or rather the killed *M. tuberculosis*) present in Freund’s adjuvant was almost taken for granted until 1989 when Charles Janeway Jr. declared that “the innate immune response (if induced) was prerequisite for an adaptive immune response” (Janeway, 1989). Janeway’s prediction was eventually proven by a number of labs using classical genetic methods, most clearly when TLR4 was identified as the receptor for lipopolysaccharide (LPS), and TLR9 was shown to recognize bacterial DNA (Poltorak et al., 1998; Hemmi et al., 2000; Dueth
The identification of pathogen associated molecular patterns (PAMPs; a group of lipid, carbohydrate, peptide, and nucleic-acid structures, broadly expressed by different microorganisms) and their associated pathogen-recognition receptors (PRRs), has revolutionized vaccine research (Janeway, 1989; Janeway and Medzhitov, 2002; Medzhitov and Janeway, 2002; Medzhitov and Janeway, 2002; Bickels et al., 2002; Janeway and Medzhitov, 2002). Identifying candidate antigens need to be delivered with appropriate adjuvants to elicit an appropriate immune response (Coler and Reed, 2005, 2009). Directed stimulation of PRR, the majority of the vaccines that have been licensed and made available for clinical use remain live, attenuated, or killed vaccines (WHO, 2004; The European Medicines Agency, 2005; WHO Department of Immunization, Vaccines and Biologicals and UNICEF Programme Division, Health Section, 2005; National Advisory Committee on Immunization, 2008; Central Drugs Standard Control Organization, 2010; U.S. Food and Drug Administration, 2011). Advances in molecular and cellular biology are rapidly revealing the nature of innate immunity and adjuvant activity. The discovery of the ability of adjuvants to enhance disease-specific immune responses using recombinant antigens has led many researchers to re-focus their vaccine development programs (Reed et al., 2009). Effective adjuvants and adjuvant formulations can utilize multiple compounds and mechanisms to achieve the desired immunological enhancement (Schu, 2010; Pashine et al., 2005; Reed et al., 2009). These mechanisms can enhance antigen presentation, leading to induction of effective humoral (B cell) and cellular (CD4 and/or CD8 T cell) responses.

Despite the dramatic advances in our understanding of defined PRR, the majority of the vaccines that have been licensed and made available for clinical use remain live, attenuated, or killed vaccines (WHO, 2004; The European Medicines Agency, 2005; WHO Department of Immunization, Vaccines and Biologicals and UNICEF Programme Division, Health Section, 2005; National Advisory Committee on Immunization, 2008; Central Drugs Standard Control Organization, 2010; U.S. Food and Drug Administration, 2011). Advances in molecular and cellular biology are rapidly revealing the nature of innate immunity and adjuvant activity. The discovery of the ability of adjuvants to enhance disease-specific immune responses using recombinant antigens has led many researchers to re-focus their vaccine development programs (Reed et al., 2009). Effective adjuvants and adjuvant formulations can utilize multiple compounds and mechanisms to achieve the desired immunological enhancement (Schu, 2010; Pashine et al., 2005; Reed et al., 2009). These mechanisms can enhance antigen presentation, leading to induction of effective humoral (B cell) and cellular (CD4 and/or CD8 T cell) responses.

Despite the dramatic advances in our understanding of defined PRR, the majority of the vaccines that have been licensed and made available for clinical use remain live, attenuated, or killed vaccines (WHO, 2004; The European Medicines Agency, 2005; WHO Department of Immunization, Vaccines and Biologicals and UNICEF Programme Division, Health Section, 2005; National Advisory Committee on Immunization, 2008; Central Drugs Standard Control Organization, 2010; U.S. Food and Drug Administration, 2011). An ideal vaccine against leishmaniasis must be safe, effective, and given its recognition as a neglected disease, affordable. As addressed earlier, it appears that a live or killed parasite vaccine will not be feasible for leishmaniasis. An inherent and major advantage of vaccines based on attenuated pathogens and inactivated viruses or bacteria is that they are sufficiently immunogenic without additional adjuvants, likely through the undefined inclusion of intrinsic PAMPs. Such activity has been revealed for the highly effective Yellow Fever vaccine (Querec et al., 2006). By contrast, protein-based vaccines, although offering considerable advantages over traditional vaccines in terms of safety and cost of production, are often less immunogenic.

Over the past few decades, many researchers have searched for genes encoding leishmanial proteins that are linked to the protective response and can induce protection against CL in experimental models (Handman et al., 1995; Mougneau et al., 1995; Shleky et al., 1995a,b, 1997, 1998; Webb et al., 1996, 1997; Probst et al., 1997; Campos-Neto et al., 2002; Coler et al., 2002). Identifying candidate antigens alone, however, is not sufficient as they need to be characterized to ensure quality and stability. More importantly, candidate antigens need to be delivered with appropriate adjuvants to elicit an appropriate immune response (Coler and Reed, 2005, Reed et al., 2009). A significant research effort has focused on adjuvants in CL (Table 1). This review outlines the efforts of several labs, including our own, regarding the use of adjuvants both in CL animal models and their impact on efficacy in the clinic.

**ALUMINUM SALTS (ALUM) AS ADJUVANT**

Introduced in the 1920s, alum became the first adjuvant to be approved by the U.S. Food and Drug Administration for use in humans (White et al., 1955; Marrack et al., 2009; Reed et al., 2009).
Although the initial and long-held theory was that alum facilitated an immune response by providing a depot, more recent studies have challenged this theory and suggest otherwise (White et al., 2008; Kundi, 2007; Frazer and Levin, 2011). Most importantly, the recent approval of MPL-Alum® for two different vaccines, Fendrix and Cervarix, has set precedence for the use of TLR4 agonists within human vaccines (Kundi, 2007; Duthie et al., 2011; Frazer and Levin, 2011).

In relation to leishmaniasis, alum has been used in combination with BCG or IL-12 and autovaccinated L. major (ALM) to protect against experimental murine CL (Kenney, 1999; Soudi et al., 2011). The first clinical study in leishmaniasis that used alum in conjunction with ALM and BCG was conducted for the treatment of VL. Data indicated that the approach was not only safe but could induce strong delayed type hypersensitivity (DTH) reactions in study volunteers (Kamal et al., 2003). More recently, alum-precipitated ALM and BCG was used as part of an immunomodulatory approach to treat post-kala-azar dermal leishmaniasis (PKDL) in Sudan (Musa et al., 2008). This randomized and double-blind study aimed to assess safety, immunogenicity, and curative potential of this regimen in patients with persistent PKDL. Patients were treated with sodium stibogluconate (SSG) + alum-precipitated ALM and BCG; SSG + alum/ALM + BCG was found to be safe and immunogenic, and demonstrated significant healing potential in persistent PKDL lesions.

The applicability of alum-based formulations for leishmania vaccines is neither supported by current knowledge regarding alum’s mechanism of action nor by clinical or experimental experience.

**INTERLEUKIN-12**

Interleukin-12, originally called natural killer cell stimulatory factor, was identified by Trinchieri and colleagues, who discovered that it can stimulate the production of IFN-γ from T cells and natural killer cells (Kobayashi et al., 1989; Chau et al., 1991; Manetti et al., 1993). Further studies demonstrated the ability of several pathogens to induce a Th1 response correlated with their capacity to stimulate the production of IL-12 (Hsieh et al., 1993; Scott, 1995). The critical involvement of IL-12 in promoting Th1 responses in vivo was demonstrated using the mouse model of CL (Syryc et al., 1993). The use of IL-12 as an adjuvant was subsequently examined in various models including the murine CL model (Syryc et al., 1993; Scott and Trinchieri, 1997; Wright et al., 2008; Metzger, 2010). Effective vaccination against L. major in susceptible mouse strains was achieved using recombinant IL-12 with soluble leishmanial antigen (SLA) and with a recombinant LACK protein (Afonso et al., 1994; Mougeau et al., 1995). Several studies have demonstrated the short-lived nature of protection in mice following immunization with recombinant LACK plus IL-12 protein. Protection waned 2 weeks after immunization, whereas protection was sustained up to 12 weeks later.

---

**Table 1 | List of adjuvants that have been used in experimental and/or clinical CL.**

| Adjuvant | Antigen | Murine CL | Human |
|----------|---------|-----------|-------|
| Alum ± BCG | ALM | ++ | Phase II |
| Alum ± CpG | SLA | ++ | ND |
| Based on TLR4 agonists | | | |
| MPL-SE | GPE3 | –/- | ND |
| | L111F, L110F | ++ | Phase II |
| | SMRT, KSAC | ++ | ND |
| GLA-SE | L10X, NS, KSAC | ++ | Phase I |
| Based on TLR7/8 agonists | | | |
| Imiquimod (Aldara) | N/A | ++ | Phase II |
| R848 | ALM | ++ | ND |
| | ALM | ++ | ND |

| Based on TLR9 agonists | | | |
| CpG | Live parasites | ++ | ND |
| | SLA | ++ | ND |
| | ALM | ++ | ND |
| | H2B | ++ | ND |
| | IL-12P70 | ++ | ND |
| LACK | ++ | ND |
| LmSTI1 | ++ | ND |
| L111F | ++ | ND |

ND: not done; +: + Protection; ±: incomplete protection

Table 1 lists adjuvants that have been used in experimental and/or clinical CL. The list includes the adjuvant, the antigen, and the response in murine and human CL models. Alum has been used in conjunction with BCG or IL-12 and autovaccinated L. major (ALM) to protect against experimental murine CL (Kenney, 1999; Soudi et al., 2011). The first clinical study in leishmaniasis that used alum in conjunction with ALM and BCG was conducted for the treatment of VL. Data indicated that the approach was not only safe but could induce strong delayed type hypersensitivity (DTH) reactions in study volunteers (Kamal et al., 2003). More recently, alum-precipitated ALM and BCG was used as part of an immunomodulatory approach to treat post-kala-azar dermal leishmaniasis (PKDL) in Sudan (Musa et al., 2008). This randomized and double-blind study aimed to assess safety, immunogenicity, and curative potential of this regimen in patients with persistent PKDL. Patients were treated with sodium stibogluconate (SSG) + alum-precipitated ALM and BCG; SSG + alum/ALM + BCG was found to be safe and immunogenic, and demonstrated significant healing potential in persistent PKDL lesions.

The applicability of alum-based formulations for leishmania vaccines is neither supported by current knowledge regarding alum’s mechanism of action nor by clinical or experimental experience.
when the IL-12 and LACK genes were delivered within a DNA construct (Gurunathan et al., 1997, 1998; Stobie et al., 2008; Mendez et al., 2001). These studies suggested that the continued presence of IL-12 as a requirement for long-lived vaccine-induced immunity.

The safety, immunogenicity, and efficacy of a vaccine combining heat-killed *L. amazonensis* with recombinant human (rH) IL-12 and alum (aluminum hydroxide gel) as adjuvant, has been assessed in rhesus macaques. When lesion development was followed after intradermal challenge, an IL-12 dose response was evident and protective immunity was demonstrated in all monkeys (12 total) that received 2 μg rIL-12 at all Ag/alum doses (Kenney et al., 1999). When vervet monkeys were immunized with ALM with or without rHL-12, despite the generation of substantial *Leishmania*-specific immune responses, no protection was observed against subsequent challenge with *L. major* parasites (Gicheru et al., 2001). The transition to use of rHL-12 in humans has proven difficult, however, as parental administration over several days was found to be highly toxic (Cohen, 1995; Wright et al., 2008).

**TLR AGONISTS – LIPID A AND DERIVATIVES**

Lipopolysaccharide, a complex amphiphilic molecule that covers the outer surface of *Escherichia coli* and other Gram-negative bacteria such as *M. tuberculosis* was the first microbial product discovered to be a TLR agonist. Although lipid A had been defined as the hydrophobic moiety of LPS for over 50 years, the elucidation of lipid A biosynthesis was not achieved until the early 1980s. The ability of the “free” lipid A molecule to induce tumor regression, endotoxic shock, interferon production, and macrophage activation generated much pathophysiological interest (Takayama et al., 1983). Determination of the lipid A structure was followed by attempts to chemically modify lipid A, generally with the intent of uncoupling its toxic effects from its potentially useful immunomodulatory properties. This resulted in the identification of an acylated diglucosamine derivative of lipid A from *Salmonella minnesota* RC595, which was then further refined to derive MPL® with reduced pyrogenicity (Pering et al., 2002).

Even though the existence of LPS receptors had been identified in the 1970s to be dependent on the integrity of a single locus known as Lps, the locus was not defined until 1998, when it was demonstrated through positional cloning to be identical to the TLR4 (TR4) locus (Skidmore et al., 1976; Poltorak et al., 1998). TLR4’s ability to utilize both the MyD88 and TRIF signaling pathways has been critical to the success of lipid A as an adjuvant. While it is not clear if a single TLR4 molecule can signal through one or both pathways at the same time, it has been suggested that MyD88/MyD88ΔMAL is required for the rapid activation of TLR4 and for the production of TNF, while TRIF stimulates a more sustained induction of NF-κB through the MyD88-independent pathway. Studies with MyD88 KO and TRIF KO mice have indicated that signaling through MyD88/MyD88ΔMAL is essential for IL-12 production, and the resulting IFN-γ, while signaling through the TRIF/TRAM pathway appears to be crucial for IL-6 production. Further research defining the roles of these two signaling pathways in TLR4 activation is required (O’Neill and Bowie, 2007).

The efficacy of MPL® was first tested in a syngeneic guinea pig cancer model, where it synergistically enhanced the ability of mycobacterial cell wall skeleton (CWS) to regress transplantable, line-10 tumor (hepatocellular carcinoma; Ribi et al., 1984). Later studies demonstrated that MPL can also enhance immune responses to both killed virus and purified proteins (Matsuhi et al., 1986). Based upon those studies adjuvating a mixture of well-defined recombinant antigens together with MPL was a logical progression for a vaccine against leishmaniasis.

Monophosphoryl lipid A was first evaluated against leishmaniasis by comparison against alternative adjuvants in a prophylactic study in the murine model of CL with *L. mexicana* with a subunit vaccine (Abelscher et al., 2000). The ability of MPL to adjuvant antigen-specific protection against experimental CL was contrasted against a panel of five other adjuvants (IL-12, QS-21, M. avium BCG, Corynebacterium parvum – now known as Propionibacterium acneus, and Detox). By its ability to protect against CL infection, Detox, an adjuvant formulation made up of MPL and mycobacterial CWS, was shown to be almost equal in efficacy to IL-12. MPL alone induced similar results, albeit with a slightly lower efficacy than either Detox or IL-12. In later studies conducted at IDRI, MPL was formulated in an oil-in-water formulation (MPL-SE) which helped improve its efficacy (Coler and Reed, 2005). Several studies have demonstrated that the inclusion of MPL-SE induces a strong type 1 profile, with high levels of IFN-γ and comparatively low levels of type 2 cytokines such as IL-4 and IL-10. Serum immunoglobulin also becomes skewed toward a higher IgG2a/IgG1 ratio when MPL is present in the vaccine formulation (Coler and Reed, 2005). Further, use of MPL within prophylactic vaccines can induce multi-functional, memory T cells, an established correlate of protection in the murine CL model (Darrah et al., 2007; Bertholet et al., 2009). Moreover, this adjuvant has shown equivalent efficacy in both murine CL and VI models (Coler et al., 2007; Goto et al., 2007).

Of the TLR agonists identified, MPL is the most advanced and is currently the only licensed adjuvant commercially available today. MPL adjuvant has proven to be a potent yet apparently non-toxic vaccine adjuvant when administered with heterologous antigens. MPL has been used extensively as an adjuvant in clinical trials for several infectious diseases and cancer indications, and to date, over 100,000 doses of MPL have been administered to human subjects in a single locus known as Lps, the locus was not defined until 1998, when it was demonstrated through positional cloning to be identical to the TLR4 (TR4) locus (Skidmore et al., 1976; Poltorak et al., 1998). TLR4’s ability to utilize both the MyD88 and TRIF signaling pathways has been critical to the success of lipid A as an adjuvant. While it is not clear if a single TLR4 molecule can signal through one or both pathways at the same time, it has been suggested that MyD88/MyD88ΔMAL is required for the rapid activation of TLR4 and for the production of TNF, while TRIF stimulates a more sustained induction of NF-κB through the MyD88-independent pathway. Studies with MyD88 KO and TRIF KO mice have indicated that signaling through MyD88/MyD88ΔMAL is essential for IL-12 production, and the resulting IFN-γ, while signaling through the TRIF/TRAM pathway appears to be crucial for IL-6 production. Further research defining the roles of these two signaling pathways in TLR4 activation is required (O’Neill and Bowie, 2007).

The efficacy of MPL® was first tested in a syngeneic guinea pig cancer model, where it synergistically enhanced the ability of mycobacterial cell wall skeleton (CWS) to regress transplantable, line-10 tumor (hepatocellular carcinoma; Ribi et al., 1984). Later studies demonstrated that MPL can also enhance immune responses to both killed virus and purified proteins (Matsuhi et al., 1986). Based upon those studies adjuvating a mixture of well-defined recombinant antigens together with MPL was a logical progression for a vaccine against leishmaniasis.

Monophosphoryl lipid A was first evaluated against leishmaniasis by comparison against alternative adjuvants in a prophylactic study in the murine model of CL with *L. mexicana* with a subunit vaccine (Abelscher et al., 2000). The ability of MPL to adjuvant antigen-specific protection against experimental CL was contrasted against a panel of five other adjuvants (IL-12, QS-21, M. avium BCG, Corynebacterium parvum – now known as Propionibacterium acneus, and Detox). By its ability to protect against CL infection, Detox, an adjuvant formulation made up of MPL and mycobacterial CWS, was shown to be almost equal in efficacy to IL-12. MPL alone induced similar results, albeit with a slightly lower efficacy than either Detox or IL-12. In later studies conducted at IDRI, MPL was formulated in an oil-in-water formulation (MPL-SE) which helped improve its efficacy (Coler and Reed, 2005). Several studies have demonstrated that the inclusion of MPL-SE induces a strong type 1 profile, with high levels of IFN-γ and comparatively low levels of type 2 cytokines such as IL-4 and IL-10. Serum immunoglobulin also becomes skewed toward a higher IgG2a/IgG1 ratio when MPL is present in the vaccine formulation (Coler and Reed, 2005). Further, use of MPL within prophylactic vaccines can induce multi-functional, memory T cells, an established correlate of protection in the murine CL model (Darrah et al., 2007; Bertholet et al., 2009). Moreover, this adjuvant has shown equivalent efficacy in both murine CL and VI models (Coler et al., 2007; Goto et al., 2007).

Of the TLR agonists identified, MPL is the most advanced and is currently the only licensed adjuvant commercially available today. MPL adjuvant has proven to be a potent yet apparently non-toxic vaccine adjuvant when administered with heterologous antigens. MPL has been used extensively as an adjuvant in clinical trials for several infectious diseases and cancer indications, and to date, over 100,000 doses of MPL have been administered to human subjects in the United States. MPL has now been shown to induce a transient, localized innate immune response and activation of DCs, leading to activation of antigen-specific T cells and enhanced adaptive immunity (Didierlaurent et al., 2009). As predicted by its ability to induce IL-12, despite the presence of alum, inclusion of MPL in AS04 biases the immune response to a strong Th1 type phenotype.

IDRI has also used MPL to spearhead several clinical trials directed against leishmaniasis. Our first trial investigated a mixture of antigens for the ability to treat drug-refractory patients suffering from mucosal leishmaniasis (ML; Badaro et al., 2006).
The trial was successful with five/six patients showing complete clinical remission at the 9-month follow-up and all six becoming asymptomatic at the 5-year follow-up examination. The antigens had been conjugated with GM-CSF at that time but adjuvant was subsequently switched to MPL-SE based practical issues and on results from our pre-clinical studies (Coler and Reed, 2005). The antigens are now expressed as a single entity within Leish F1 chimeric fusion protein, rendering the antigen configuration more accessible to cost-effective, large-scale production. This vaccine was tested in both healthy Columbian and Indian volunteers with neither history of leishmaniasis or sub-clinical infection with L. braziliensis/L. panamensis (detection based on the Montenegro skin test). An increase in anti-Leish F1 IgG response was observed in all, and an antigen-specific IFN-γ response was observed in the majority of recipients (Velez et al., 2009; Chakravarty et al., 2011; Duthie et al., 2012). Based on these results we concluded that the vaccine was safe and well-tolerated in subjects with and without evidence of prior infection. Additionally, we have evaluated the LEISH-F1 + MPL-SE vaccine as an adjunct immunotherapy with standard chemotherapy in both CL and ML. The vaccine was found to be safe and immunogenic in both CL and ML patients and appeared to shorten their time to cure when used in combination with meglumine antimoniate chemotherapy. Further treatment of ML patients with vaccine helped induce a memory T cell subset, associated with clinical cure (Ilanas-Cuestas et al., 2010). These studies have proven that the vaccine is safe for use in both healthy and infected patients, and is able to induce a memory response that could help protect against future infections.

We have further optimized the adjuvant MPL by developing a synthetic lipid A derivative that exerts manufacture and provides a more homogeneous final product. Like MPL, formulations of glucopyranosyl lipid adjuvant (GLA) also signals through TLR4 (Coler et al., 2011). When formulated with SE, an oil-in-water emulsion, and mixed with antigen, the resulting Ag + GLA-SE mixture induces potent Th1 immune response in mice. Studies show that GLA-SE and MPL-SE adjuvanted responses to be dose-dependent, skewing toward a Th1-like response in mice that receive either of these TLR4 agonists. We have also established that GLA-SE is a more potent adjuvant compared to MPL-SE in terms of stimulating antigen-presenting cell activation and inducing greater IFN-γ secretion by antigen-specific T cells. Low doses of GLA-SE are capable of inducing a high frequency of multi-functional effector T cells (Bertholet et al., 2009). Recent work has also suggested that either TLR4-based adjuvant (MPL and GLA) represent good candidates for CL immunotherapy when coupled with the TLR9 ligand, CpG (Raman et al., 2010). Together, these data indicate considerable promise for the development of a safe, effective, and inexpensive vaccine for both prophylactic and therapeutic application against leishmaniasis.

**TLR8 AGONISTS – RESIQIUMOD AND IMIQIUMOD**

Initial characterization studies had demonstrated that imiquimod could induce production of antiviral cytokines, including IFN-α, TNF, and IL-1β, from monocytes (Testerman et al., 1995). Imiquimod could also augment the Th1 immune response by mediating the release of IL-12 and IFN-γ from macrophages (Wagner et al., 1999). It was revealed, that treatment of L. donovani-infected macrophages with imiquimod resulted in killing of intracellular amastigotes and that this was dependent on the production of NO by the treated macrophages (Buates and Matlashewski, 1999). Through a gene array approach it was further demonstrated that, consistent with the ability of imiquimod to activate killing of intracellular Leishmania amastigotes, imiquimod’s related compound S-28463 induced gene expression associated with macrophage activation and an inflammatory response including NF-κB, IL-1, iNOS, and MIP-1 (Buates and Matlashewski, 2001). Only later was it discovered that imiquimod structurally resembled single stranded RNA that was capable of activating macrophages through stimulating the TLR7 pathway (Hemmi et al., 2002).

Based on these experimental observations and because topical treatment with imiquimod had obtained FDA approval in 1997 (for the treatment of cutaneous cervical warts caused by human papilloma viruses infections), a small human trial was conducted to treat CL patients (Arevalo et al., 2001). This study, supported by WHO-TDR was conducted in Peru on 12 CL patients infected with L. V. braziliensis that had failed an initial treatment with pentavalent antimony. Study subjects were given a second course of pentavalent antimony plus topical imiquimod every 2 days for 20 days. The topical application of imiquimod on the lesions was well tolerated and 11 out of 12 patients were cured at the 3-month follow-up period (Arevalo et al., 2001). Subsequently a placebo controlled study was conducted on 40 CL patients who had failed treatment with pentavalent antimony and were given a second treatment with the combination of pentavalent antimony plus topical imiquimod or a placebo cream. The outcome was a 72% cure rate for the group receiving imiquimod versus 35% cure for the group receiving placebo at the 3-month follow-up (Miranda-Verastegui et al., 2005). Overall these observations indicated that combination therapy with topical imiquimod plus pentavalent antimony was well tolerated and this represented a good option for treating patients who had failed the first line treatment with pentavalent antimony alone.

A subsequent study was undertaken to determine whether topical imiquimod combined with pentavalent antimony could be considered as a first line therapy for CL in Peru (Miranda-Verastegui et al., 2009). This randomized placebo control study showed that the combination treatment of imiquimod plus pentavalent antimony performed better (75% cure) than placebo plus pentavalent antimony (58% cure) at the 3-month follow-up period, but that the difference was not statistically significant. A study conducted in Iran involving L. tropica infections reported that there was no beneficial effect of combining topical imiquimod with pentavalent antimony (Eirooz et al., 2006). It is possible that the topical imiquimod was unable to penetrate to the infected cells because, in comparison to the ulcer lesions typical of New World CL, L. tropica infections are typically nodular.

An interesting recent report describes the treatment of a 7-year-old boy with a lesion on the left cheek caused by a L. infantum infection (Hervas et al., 2011). For more than a year this patient had failed various treatments, including topical paromomycin, intralesion injection of pentavalent antimony, photodynamic...
therapy, and two courses of intravenous liposomal amphi-
tericin B. The patient was finally treated with topical imiquimod
and cured within a month (Hervas et al., 2011). Treatment with
topical imiquimod alone was attempted on L. V. braziliensis infec-
tions in Peru and although this provided initial lesion regression,
cure was not obtained (unpublished observation). For this
reason, imiquimod has typically been used in combination
therapy in the New World. Based on the available published evi-
dence, a World Health Organization appointed expert committee
on control of leishmaniasis recently updated it treatment guide-
lines to now include the use of imiquimod in combination with
pentamidine antimony as a second-line therapy for CL in the New
World (VHIO, 2010).

Given the adjuvant properties of topical imiquimod in treat-
ment of infectious diseases, topical imiquimod has also been tested
as a vaccine adjuvant in an experimental model of CL in BALB/c
mice. It was found that application of topical imiquimod on
the skin prior to subcutaneous immunization with crude Leish-
mania antigen provided increased protection against challenge
infection compared to immunization of crude antigen alone and
this was associated with an enhanced Th1 response against the
vaccine antigen (Zhang and Mathlouthi, 2008). Subsequently,
itis was likewise shown that topical application of imiquimod at
the site of subcutaneous injected Plasmodium falciparum cir-
cumsporozoite (CS) peptide elicited a strong Th1 response and
high antibody titers that provided protection against a challenge
infection (Otranto et al., 2009). These studies show that further
consideration should be given to using topical imiquimod as a vac-
cine adjuvant for any pathogen antigen delivered subcutaneously,
particularly where a Th1 response is required for protective
immunity.

TLR9 AGONISTS – CpG AND IMMUNOMODULATORY OLIGOS

The concept of immunostimulatory DNA was first identified in
the early 1990s during studies on BCG-mediated tumor resistance
(Tokunaga et al., 1999). The identification of CpG dinucleotide
motifs within prokaryotic DNA that could activate B cells galva-
nized research efforts (Krieg et al., 1995). The adjuvant properties
of CpG were exploited within experimental vaccines for a num-
ber of diseases including lymphoma, hepatitis, malaria, influenza,
and leishmanial before the discovery of its innate receptor,
TLR9, in 2000 (Lipford et al., 1997b; Woodridge et al., 1997;
Brazolot Millan et al., 1998; Davis et al., 1998; Moldoveanu et al.,
1998; Zimmermann et al., 1998; Jones et al., 1999; Hemmi et al.,
2000). These findings also provided an additional dimension to be
explored, i.e., the possibility of intentionally incorporating these
motifs within DNA vaccines (Klinman et al., 1997; Li et al., 2004).
While it was first believed that a single type of optimal CpG motif
would work in all applications, later reports showed that specific
motifs of CpG-containing immunostimulatory oligodeoxynu-
cleotides (CpG ODNs) could vary dramatically in their ability to
induce individual immune effects (Kollar et al., 2001; Krug et al.,
2001). Three classes of CpG ODN are now recognized – A-class
ODN promote the highest degree of NK cell stimulation and also
IFN-α secretion by plasmacytoid DCs. B-class ODN stimulate
strong B cell and NK cell activation, as well as cytokine production;
C-class ODN combine the effects of A- and B-class CpG ODN.

The ability of CpG ODN to stimulate macrophages and dendritic
cells to synthesize several cytokines, including IL-12, IL-18, TNF-α,
and IFNs (IFN-α, IFN-β, and IFN-γ), to upregulate stimulatory
molecules such as CD40 and MHC class II, and to enhance the abil-
ity of dendritic cells to present soluble protein to class I-restricted
T cells, make CpG ODN a good option as an adjuvant (Klinman
et al., 1996, 2000).

Initially, the CL mouse model was used to showcase the ability
of CpG ODNs to switch the Th2 response associated with the dis-
case to a strong Th1 response. This switch has now been associated
with IL-12-dependent production of IFN-γ, an attractive quality
for a CL vaccine (Lipford et al., 1997b; Zimmermann et al., 1998;
Walker et al., 1999; Fukao et al., 2002; Flynn et al., 2005; Hutchins
et al., 2005; Yang et al., 2010). The first studies using CpG ODNs
as an adjuvant within prophylactic vaccines for CL demonstrated
that inclusion of CpG helped to induce long-term immunity that
protected against the parasite (Stacey and Blackwell, 1999; Walker
et al., 1999). Further studies demonstrated that this protection is
reliant on CD4 and CD8 T cell help, both of which had been shown
to be important in L. major infection and induced when CpG was
used as an adjuvant (Lipford et al., 1997a; Belkaid et al., 2002b;
Rhee et al., 2002).

Later studies by Mendez et al. (2003), showed that mice vac-
cinated with live parasites plus CpG ODNs displayed a transient
inflammation at 3–5 weeks, after which time little or no dermal
pathology was observed. The resolution of the transient inflam-
mation and parasite burden in the ears of CpG ODN-treated mice
coincided with the decrease of CD4 T cells in the site, whereas these
cells began to accumulate in the ears of unvaccinated mice by 6
weeks after L. major infection. These responses are induced via
activation of dermal DCs acting in an IL-6 dependent manner
(von Stebut et al., 1998; Wu et al., 2006). Activation of these der-
mal DCs eliminates the silent phase of the infection by altering
the natural kinetics of Treg cell accumulation that usually occurs
in the skin after L. major challenge (Belkaid et al., 2000, 2002a;
Wu et al., 2006). Recently, the same group reported the unusual
IL-2 production by CD11c+ DCs in the skin of mice vaccinated
with Lm/CpG. This unusual secretion was concomitant with a
peak in IFN-γ-producing NK cells and CD4+ T cells and the
control of parasite growth (Laubs et al., 2009). It has now been
shown that inclusion of CpG ODN in the vaccine also enhances
the proliferation of Th17 cells, which in turn aids the develop-
ment of a protective cell-mediated immunity against the parasite
(Wu et al., 2010). The Th17 response was shown to be dependent
upon release of vaccine-induced IL-6 identified in earlier studies
(Wu et al., 2006). Neutralization of IFN-γ and, in particular, IL-17,
caus ed increase parasite burdens in Lm/CpG-vaccinated mice.
IL-17R-deficient Lm/CpG-vaccinated mice developed lesions, and
despite displaying normal IL-12 levels, showed a decrease in IFN-γ
production. Neutrophil accumulation was also decreased in the IL-
17R-deficient Lm/CpG-vaccinated mice but the number of Treg
increased. The most striking observation in all these studies was
that mice treated with CpG ODNs had increased levels of IL-10 in
their draining lymph nodes, and only a transient increase in the
number of Tregs at the site of infection, compared to control ani-
mals (Mendez et al., 2003; Wu et al., 2006). Thus, vaccination with
live parasites and CpG ODNs appears to not only enhance adaptive
immunity but also to modulate the response of innate immune cells, thereby inhibiting parasite growth and the development of vaccine-induced pathology.

Interestingly, CpG ODNs induce similar responses even when mixed with recombinant antigens (Rhee et al., 2002; Coler and Reed, 2005; Darrah et al., 2007). Vaccination with CpG ODN induced a high frequency of multi-functional T cells, a positive correlate of protection, especially in the CL model. Responses generated with these defined vaccines were established as early as 10 days after immunization, suggesting CpG ODN could be good adjuvants for both prophylaxis and therapy (Darrah et al., 2007; Raman et al., 2010). These responses were shown to remain consistent over prolonged periods of time, although they did wane after 6 months (Rhee et al., 2002; Darrah et al., 2007). Further investigations showed an increase in IL-10 levels in sera after immunization with vaccines containing CpG ODNs (Darrah et al., 2010). Inhibition of innate IL-10 produced by antigen presenting cells (APCs) at the time of immunization significantly enhanced the magnitude of the response and the extent of Th1 differentiation and, importantly, increased protection. This particular aspect of the adjuvant makes it much more attractive option for immunotherapy, with the possibility of preventing pathology. Studies performed by IDRI demonstrate that treatment of L. major-infected mice with CpG in conjunction with L110F and MPL-SE decreases both parasite burden and infection-induced pathology (Raman et al., 2010).

CpG ODN have not yet been used as a vaccine adjuvant against leishmaniasis in human subjects. Preliminary studies involving vaccination of non-human primates with vaccine formulations containing non-human primates with vaccine formulations have yielded positive results, inducing strong Th1 responses in both prophylactic and therapeutic settings (Walker et al., 1999; Flynn et al., 2003).

Several synthetic ODN are currently in development for the treatment of various cancers (Krieg, 2008). These ODN use a nuclease-resistant phosphorothioate backbone that improves the half-life in the body from just a few minutes (for unmodified native DNA) to approximately 48 h. Immune modulatory oligonucleotides (IMOs) that stimulate TLR9 signaling have been developed and tested, for anti-tumor activity in mouse models, both as a monotherapy and in combination with chemotherapy agents. A number of these IMOs have also entered Phase I trials (Agrawal and Kandimalla, 2007; Dynavax Technologies, 2010; Hennessy et al., 2010). Similar Immunostimulatory sequences (ISS), comprised of short DNA sequences that have been shown to induce production of memory T cells and a Th1 response, and are also under investigation (Agrawal and Kandimalla, 2007). A potential advantage of ISS is that they can be used alone or linked to antigens to suppress Th2 response (Barry and Cooper, 2007).

Coley Pharmaceutical Group (Wellesley, MA, USA; currently Pfizer) developed CPG7909, which has been tested as a vaccine adjuvant in human clinical trials in the context of several vaccines (including flu, hepatitis, and malaria) with promising results (Cooper et al., 2004a,b; Mullen et al., 2008). The immunostimulatory effect of CPG7909 in these vaccines was shown to depend on the association of the CpG and antigen to alum (Aebig et al., 2007; Mullen et al., 2007). Addition of CPG 7909 to the malaria vaccine, AMA1-C1/alum vaccine in naïve (not exposed to malaria) individuals was shown to elicit significantly higher AMA1 specific immune IgG compared to individuals who only received AMA1-C1/alum (Mullen et al., 2008). Later studies on these samples showed that addition of CPG 7909 enhanced the kinetics, magnitude, and longevity of responses (Uptompton et al., 2009). In contrast the same CpG-containing malaria vaccine did not enhance the acquisition of memory in semi-immune adults living in Mali (Traore et al., 2009). Understanding the molecular basis of this apparent refractoriness to TLR9 agonist in the endemic population is pertinent and of significant interest to vaccinology.

**IMPORTANCE OF FORMULATION**

Modifications to enhance vaccine potency were made early on in vaccine development history. For instance, “lipovaccines,” or homogenized dried bacterial cells mixed with oil, were first reported in 1916 (Ardbard and Fox, 1916, Pinoy, 1916a,b). This vaccine formulation increased the potency of killed bacterial vaccines in human subjects, reducing the high doses of bacterial cells and number of immunizations required, making them more comparable in efficacy to vaccines based on live-attenuated organisms such as smallpox, which only required one dose (Whitmore, 1919; Lewis and Dodge, 1920).

Formulation effects on vaccine antigens and adjuvant efficacy continue to remain critical. For example, CpGs formulated with particle-based platforms (i.e., alum, oil-in-water emulsion, or polymeric particles) induces increased total antibodies and Th1 responses in a variety of disease and animal models compared to either formulation component alone (Brazolot Millan et al., 1998; Ott et al., 2002; Ioininou et al., 2003; Linghous et al., 2006; Singh et al., 2007; Wack et al., 2008; Salem and Weiner, 2009; Fox et al., 2010a,b). The most abundant data regarding the importance of seemingly subtle formulation variations involve TLR4 agonists. For instance, AS01 (a liposomal formulation containing MPL and the saponin adjuvant QS21) induced higher anti-parasite antibodies (with less reactivity) compared to an emulsion formulation of the same molecules in a malaria vaccine clinical trial (Owusu-Agyei et al., 2009). Other TLR4 agonist formulation comparisons include oil-in-water emulsion vs. aqueous suspension or alum-adsorbed; the emulsion formulation was generally superior, inducing qualitative and quantitative differences in immune responses (Hui and Hashimoto, 2008; Loussada-Dietrich et al., 2011).

Several leishmaniasis vaccine studies employed formulation technologies to improve immune responses, especially liposomes. Lipid composition clearly influences immune responses, with synthetic saturated long-chain phospholipid structures inducing more protective responses and greater Th1 bias than unsaturated egg phosphatidylcholine in BALB/c mice or hamsters immunized with liposomal leishmania antigens (Kühl et al., 1989; Mazumdar et al., 2005; Bader et al., 2009a). Liposome size, charge, and stability can be modified by different manufacturing conditions and additional components such as charged or PEGylated headgroups and cholesterol. Interestingly, liposomes were shown to reduce the toxicity of incorporated Lipid A structures (Richards et al., 1989). Another study showed that co-encapsulation of leishmania
antigens and adjuvant (pDNA) in liposomes increased protective efficacy by twofold compared to encapsulation of only the antigen (Marzender et al., 2007). Likewise, co-encapsulation of leishmania antigen and CpG in polymeric nanoparticles showed the strongest protective responses in BALB/c mice compared to other formulation variations (Talagoodi et al., 2011). Shimizu et al. (2007) confirmed the importance of leishmania antigen encapsulation in liposomes and augmented protective immune responses further by targeting the liposome to mannose receptors on macrophages. Liposome surface charge was also found to affect immune responses to leishmania antigen, with neutral surface charge resulting in smallest footpad swelling, lowest splenic parasite burden, highest IgG2a/IgG1 ratio, highest IFN-γ production, and lowest IL-4 production compared to cationic or anionic liposomes (Badiei et al., 2009b). The above studies indicate that particulate formulations such as liposomes can serve as adjuvants simply through improved antigen delivery mechanisms, although co-formulation with additional immunostimulatory molecules may further improve immune responses (Kasturi et al., 2011).

Other important vaccine adjuvant formulations include ISCOMs, ISCOMATRIX, and virosomes. ISCOMs, or immune-stimulating complexes, are particulate antigen delivery system that consists of antigen, phospholipid, cholesterol, and saponin structures (Morein et al., 2007). ISCOMs have shown promising adjuvant activity, and induced protective immunity in a number of disease models, including murine CL although reactivity and inefficacy was reported in some studies (Pappalopoulou et al., 1998; Sjolander et al., 1998a,b; Morein et al., 2007; Middleton et al., 2009; Clements et al., 2010). ISCOMATRIX, is a particulate adjuvant that has essentially the same structure of ISCOMs but without antigen. Antigens can be formulated with the ISCOMATRIX to produce ISCOMATRIX vaccines that can provide the similar antigen presentation and immunomodulatory properties as the ISCOMs but with much broader application as they are not limited to hydrophobic membrane proteins (Sun et al., 2009). ISCOMATRIX is a more well-defined platform that under controlled conditions, form cage-like structures typically 40 nm in diameter. The ISCOMATRIX™ adjuvant has been formulated with a wide range of antigens to produce ISCOMATRIX™ vaccines with great success but has not been tested in CL yet (McKenzie et al., 2010). Virosomes, like liposomes, consist of phospholipid vesicles. However, virosomes also include fusogenic proteins (hemagglutinin and neuraminidase) for enhanced antigen processing (Metcalfe and Gluck, 2006). Influenza® (influenza) and Epicell® (hepatitis A) are virosome-based vaccines manufactured by Crucell and approved for use in many countries.

In order to optimize vaccine formulations, an array of parameters must be investigated. Formulation manufacturability and cost are often taken for granted or not considered in early development stages. However, these factors can play a critical role in ultimate product success (Hillman, 1966, 1999). Other important factors include particle size, degradability, shape, stability, and release kinetics (Mueller et al., 2004; Garidel et al., 2005; Mohanan et al., 2010). Numerous challenges remain related to adjuvant development, especially in the context of neglected tropical diseases such as leishmaniasis, but these can be overcome by using a systematic approach.

SUMMARY

Experimental CL has become a standard for investigating the development of T helper cell response and is now well established as the classic textbook example of the Th1/Th2 paradigm. Alongside the rapid advances in PRR discovery, this model has served to significantly advance our understanding of vaccine adjuvants. In the current era of translational biology, it is therefore ironic that few agonists (only those engaging TLR4 and TLR 7/8) have advanced into clinical trials against leishmania infection of humans (Table 1). Regardless, it is our hope that the advancement of vaccine adjuvants and improved understanding of the clinical situation will ultimately combine to develop effective tools to control leishmaniasis.

ACKNOWLEDGMENTS

We would like to thank Dr. Anthony Desbiens for critically reviewing the manuscript and the Clinical group at IDRI, especially Dr. Franco Piazza, Mr. Zachary Sagawa, and Ms. Jill Ashman for their constructive comments. Leishmania vaccine and adjuvant development work at IDRI has been supported in part by Grants 39129 and 42587 from the Bill & Melinda Gates Foundation and Grant R01-AI025038 from the National Institutes of Health. Greg Matlashewski acknowledges support from the Canadian Institutes of Health Research, WHO Special Program for Research and Training in Tropical Diseases (TDR) and Drugs for Neglected Diseases Initiative.

REFERENCES

Achard, C., and Foui, C. (1916). Sur l’emploi des corps gras animaux véhicules des vacins microbien. Compt. Rend. Soc. Biol. 79, 209–211.
Aebi, J. A., Mullen, G. E., Dobrescu, A., Achard, C., and Foix, C. (1916). Synthetisches agonisten der Toll-like Receptor-4 (TLR 4) und ihre Wirkung. In: Immunologische Methoden 525, 139–146.
Abed, I., Muller, E., Dobrescu, A., Rambii, K., Lambert, L., Auer, Popova, O., Long, C. A., Saur, A., and Maki, A. P. (2007). Formulation of vaccines containing CpG oligonucleotides and alum. J. Immunol. Methods 323, 139–146.
Armijos, R. X., Wiegel, M. M., Aviles, T. C., Najar, E., Alvarez, E., Matlashewski, G., and Llanos-Cuentas, A. (2001). Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847–1851.
Arnaiz, E. X., Wiegol, M. M., Aviles, H., Maldonado, R., and Racines, J. (1998). Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177, 1352–1357.
Badiei, A., Lobo, L., Mounes, A., Netto, E. M., Modabber, J., Cantoni-Netto, E., Colet, R. N., and Reed, S. G. (2006). Immunotherapy for drug-refractory mucosal leishmaniasis. J. Eur. Acad. Derm. 194, 1131–1139.
Badiei, A., Jeffers, M. R., Khamesipour, A., Samiei, A., Novrast, B. Kheiri, M. T., Barford, F., McMaster, W. R., and Matlashewski, G. (2004). Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major
Birnbaum, R., Haskell, J., Vanchinathan, B., Bertholet, S., Goto, Y., Carter, L., Bhatia, M., Barry, M., and Cooper, C. (2007).

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vac-

Leishmania major surface glycoprotein of (rgp63): the role of liposome charge on immune response and protection of dogs against experimental canine leishmaniasis. Rasmussen, W., Davis, H. L., Wald-

Birnbaum, R., Haskell, J., Vanchinathan, B., Bertholet, S., Goto, Y., Carter, L., Bhatia, M., Barry, M., and Cooper, C. (2007).

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.

Belkaid, Y., von Stebut, E., Mendez, R., Piccirillo, C. A., Mendez, R., Raman et al. Adjuvants for metabolically active leishmaniasis. G. (2009). Optimized subunit vacc.
Adjuvants for Leishmania vaccines

Frazier, I. H., and Levin, M. J. (2011). Paradigm shifting vaccines: prophylactic vaccines against lethal vaccinia-virus infection and against human papillomavirus cancer. Curr. Opin. Infect. Dis. 24, 268–279.

Hakim, T., Tanabe, M., Teraiuchi, Y., Ota, T., Matsuda, A., Aono, T., Kudowaki, T., Takahashi, T., and Koyasu, S. (2012). IFN-β-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875–881.

Garadal, P., Rappold, M., Schromm, A., Bier, J., Lehnert, K., András, L., Koch, M. H., and Brandenburg, K. (2005). Unintended effects on vaccine mobility and aggregate structure of lipopolysaccharide from Salmonella enterica subsp. in a decrease of its biological activity. Res. Microbiol. 157, 322–330.

Gechev, M., Oblož, J. O., Ajúk, C. O., Orago, A. S., Miklósi, B., and Pötting, P. (2003). Vesicular monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. J. Infect. Dis. 189, 245–251.

Getz, Y., Bogatkin, I. Y., Berholst, S., Coler, N. R., and Reed, S. G. (2005). Protective immunization against visceral leishmaniasis using Leishmania sp. 4-oxo-muramyl tripeptide formulated in adjuvant. Vaccine 25, 7490–7497.

Guerin, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 71, 287–295.

Handman, E., Symons, F. M., Baldwin, S. A., and Verthelyi, D. (2005). Preclinical assessor-blind controlled trial. Arch. Dermatol. 141, 1329–1334.

Frim, B., Wang, V., Sacks, D. L., Seder, R. A., and Vezdel, D. (2005). Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type I DNA adjuvants. Leukemia 19, 1673–1679.

Frim, B. C., Duell, T. S., Choiko, J., Anderson, R. C., Reed, S. G., and Waldvogel, T. A. (2010a). Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs. Biopharm. Drug Dis. 31, 519–527.

Frim, B. C., Frické, M., Reed, S. G., and Ingott, C. G. (2010b). Synthetic and natural TLR agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303–321.

Frazier, I. H., and Levin, M. J. (2011). Paradigm shifting vaccines: prophylactic vaccines against lethal vaccinia-virus infection and against human papillomavirus cancer. Curr. Opin. Infect. Dis. 24, 268–279.

Hakim, T., Tanabe, M., Teraiuchi, Y., Ota, T., Matsuda, A., Aono, T., Kudowaki, T., Takahashi, T., and Koyasu, S. (2012). IFN-β-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875–881.

Garadal, P., Rappold, M., Schromm, A., Bier, J., Lehnert, K., András, L., Koch, M. H., and Brandenburg, K. (2005). Unintended effects on vaccine mobility and aggregate structure of lipopolysaccharide from Salmonella enterica subsp. in a decrease of its biological activity. Res. Microbiol. 157, 322–330.

Gechev, M., Oblož, J. O., Ajúk, C. O., Orago, A. S., Miklósi, B., and Pötting, P. (2003). Vesicular monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. J. Infect. Dis. 189, 245–251.

Getz, Y., Bogatkin, I. Y., Berholst, S., Coler, N. R., and Reed, S. G. (2005). Protective immunization against visceral leishmaniasis using Leishmania sp. 4-oxo-muramyl tripeptide formulated in adjuvant. Vaccine 25, 7490–7497.

Guerin, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 71, 287–295.

Handman, E., Symons, F. M., Baldwin, S. A., and Verthelyi, D. (2005). Preclinical assessor-blind controlled trial. Arch. Dermatol. 141, 1329–1334.

Frim, B., Wang, V., Sacks, D. L., Seder, R. A., and Vezdel, D. (2005). Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type I DNA adjuvants. Leukemia 19, 1673–1679.

Frim, B. C., Duell, T. S., Choiko, J., Anderson, R. C., Reed, S. G., and Waldvogel, T. A. (2010a). Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs. Biopharm. Drug Dis. 31, 519–527.

Frim, B. C., Frické, M., Reed, S. G., and Ingott, C. G. (2010b). Synthetic and natural TLR agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303–321.

Frazier, I. H., and Levin, M. J. (2011). Paradigm shifting vaccines: prophylactic vaccines against lethal vaccinia-virus infection and against human papillomavirus cancer. Curr. Opin. Infect. Dis. 24, 268–279.

Hakim, T., Tanabe, M., Teraiuchi, Y., Ota, T., Matsuda, A., Aono, T., Kudowaki, T., Takahashi, T., and Koyasu, S. (2012). IFN-β-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875–881.

Garadal, P., Rappold, M., Schromm, A., Bier, J., Lehnert, K., András, L., Koch, M. H., and Brandenburg, K. (2005). Unintended effects on vaccine mobility and aggregate structure of lipopolysaccharide from Salmonella enterica subsp. in a decrease of its biological activity. Res. Microbiol. 157, 322–330.

Gechev, M., Oblož, J. O., Ajúk, C. O., Orago, A. S., Miklósi, B., and Pötting, P. (2003). Vesicular monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. J. Infect. Dis. 189, 245–251.

Getz, Y., Bogatkin, I. Y., Berholst, S., Coler, N. R., and Reed, S. G. (2005). Protective immunization against visceral leishmaniasis using Leishmania sp. 4-oxo-muramyl tripeptide formulated in adjuvant. Vaccine 25, 7490–7497.

Guerin, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 71, 287–295.

Handman, E., Symons, F. M., Baldwin, S. A., and Verthelyi, D. (2005). Preclinical assessor-blind controlled trial. Arch. Dermatol. 141, 1329–1334.

Frim, B., Wang, V., Sacks, D. L., Seder, R. A., and Vezdel, D. (2005). Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type I DNA adjuvants. Leukemia 19, 1673–1679.

Frim, B. C., Duell, T. S., Choiko, J., Anderson, R. C., Reed, S. G., and Waldvogel, T. A. (2010a). Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs. Biopharm. Drug Dis. 31, 519–527.

Frim, B. C., Frické, M., Reed, S. G., and Ingott, C. G. (2010b). Synthetic and natural TLR agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303–321.
Kobayashi, M., Fitz, L., Ryan, M., Klinman, D. M., Yi, A. K., Beaucage, Kenney, R. T., Sacks, D. L., Sypek, J. Kedzierski, L., Curtis, J. M., Doherty, Klinman, D. M., Yamshchikov, G., and Raman et al. Adjuvants for Krieg, A. M. (2008). Toll-like receptor 9 Alam, M., Kwissa, M., Villinger, F., Acad. Sci. U.S.A. killer cell stimulatory factor (NKSF), identification and purification of natural S., Loudon, R., Sherman, F., Perussia, Hewick, R. M., Clark, S. C., Chan, horn, V., Ishii, K. J., Takeshita, D., Gursel, I., Ishii, K. J., Takeda, K., Akira, S., Arai, K., Ueda, Y., and Matsumoto, Y. (2011). Silica crystals and alu- man salt regulates the production of proinflammatory in macrophages via NLAP-inflammasa-immune-independent mechanisms. Immunity 34, 514–528. Laza, E. M., Wu, W., and Mendes, S. (2008). Vaccination with live Leish- mania major and CPG DNA promotes interferon-2 production by dendritic cells and NK cell activation. Clin Vaccine Immunol. 15, 1681–1686. Lewis, P. A., and Dodge, F. W. (1920). "Fimmu-03-00144" — 2012/6/8 — 17:52 — page 12 — #12...
Momeni, A. Z., Jalayer, T., Emamjomeh, Moldoveanu, Z., Love-Homan, L., Mohanan, D., Slutter, B., Henriksen-Miranda Verastegui, C., Tulliano, G., Middleton, D., Rockman, S., Pearse, M., Metcalfe, I. C., and Gluck, R. (2006). *Vaccine* Virol. Raman et al. Adjuvants for “Virosomes for vaccine delivery,” *Vaccine* Virol. Mullen, G. E., Ellis, R. D., Miura, K., Mullen, G. E., Aebig, J. A., Dobrescu, M., Vezina, S., Osei-Kwakye, K., Adjei, E., Sylverken, J., Adjei, A., Osei, D., Osei Akoto, A., Osei-Kwesigye, G., Adeyi, G., Samban, D., Ajanja, S., Kavan, Y., Yokomoto, J., Ofori-Anyinam, O., Leach, A., Liwet, K., Derouin, M., M., Dahou, M. C., Cohen, J., Baliga, W. R., Swarup, H., Chandran, D., Gopong, J., O. Milligan, P., Amro, S., Achilles, G., Moores, B., and Evans, J. (2009). Randomized controlled trial of RTS,S/AS02D malaria candidate vaccines given according to different schedules in Ghanaian children. *PLoS ONE* 4, e5832. doi: 10.1371/journal.pone.0005832.

Araman, V. Y., Bhata, P., Parche, A., Wither, J., Bailey, B. H., O'Tonnell, J., Putthibh, S., Gudmunson, J. A., O'Higgins, B. M., Drabo, M., Aldro, B., and Poplin, B. (2006). Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR 7, 8, 9 and to stimulate polyspecific immunity. *J. Exp. Med.* 201, 413–424.

Seydel, U. (2004). Aggregates are the first-line therapy for human cutaneous leishmaniasis in Peru. *J. Exp. Med.* 201, 945–950.

Bhatia, N., Bajka, K., Bohl, P., Das, P. D., and Bhatia, S. (2008). Multiple immune responses to a novel TLR-7 agonist, imiquimod. *Science reporting in immunity and vaccine development.* Trends Immunol. 29, 213–219.
Shimizu, Y., Takagi, H., Nakayama, Scott, P. (1998). Differentiation, regulation, and function of antigen-presenting cells in immune responses to Leishmania major. J Immunol. 161, 6171–6179.

Skeiky, Y. A., Benson, D. R., Costa, J. L., Skeiky, R. M., Spath, G. F., Beverley, S. M. (1995). Genetic linkage between the innate immune response and Th1 response. J Exp. Med. 177, 1707–1712.

Talafahi, M., Khamashe, O., and Jadali, M. R. (2011). Immunization against leishmaniasis by PLGA nanoparticles encapsulated with anti-cloned Leishmania major (ALM) and ISCOMATRIX. Vaccine 29, 4366–4401.

Tokunaga, T. (2006) [A review on mechanisms of anti-tumor action of BCG (author’s transl)]. Kekkaku 55, 551–557.

Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA (pseudomonas DNA). Kekkaku 77, 1–11.

Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA (pseudomonas DNA). Kekkaku 77, 1–11.

Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA (pseudomonas DNA). Kekkaku 77, 1–11.

Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA (pseudomonas DNA). Kekkaku 77, 1–11.
Adjuvants for Leishmania vaccines

Wagner, T. L., Ahonen, C. L., Walker, P. S., Scharton-Kersten, T., Wack, A., Baudner, B. C., Hilbert, A. von Stebut, E., Belkaid, Y., Jakob, Raman et al. Adjuvants for immune response modifiers, R-848, Vasikos, J. P., and Tomai, M. R. L., Smith, R. M., Reiter, M.ture, A. M., Gibson, S. J., Miller, temic therapy for leishmaniasis via protective immunity and provide systemic adjuvant effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides containing CpG motifs induce the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 40, 2517–2527. Wu, W., Weigand, L., Belkaid, Y., and Mendes, S. (2006). Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur. J. Immunol. 36, 3326–3347. Yang, Z., Zhang, X., Derakh, P. A., and Moss, D. M. (2010). The regulation of Th1 responses by the p38 MAPK. J. Immunol. 183, 6205–6213. Zhang, W. W., and Matlashewski, G. (2008). Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76, 3777–3783. Zimmermann, S., Egger, O., Hausmann, S., Lipford, G. R., Ricken, M., Wagner, H., and Hung, K. (1996). CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627–3630.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Received: 07 February 2012; paper pending publication: 13 March 2012; accepted: 18 May 2012; published online: 11 June 2012 Citation: Raman VS, Dhoble HH, Fox CB, Matlashewski G and Reed SG (2012) Adjuvants for Leishmania vaccines: from models to clinical application. Front. Immun. 3:144. doi: 10.3389/ frontimm.2012.00144 This article was submitted to Frontiers in Microbial Immunology, a specialty of Frontiers in Immunology. Copyright © 2012 Raman, Dhoble, Fox, Matlashewski and Reed. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which per- mit non-commercial use, distribution, and reproduction in other forums, pro- vided the original authors and source are credited.

www.frontlineimm.org June 2012 | Volume 3 | Article 144 | 15